- Home
- NFJ vs IMTX Comparison
NFJ vs IMTX Comparison
Compare NFJ & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFJ | IMTX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NFJ | IMTX |
|---|---|---|
| Price | $15.03 | $9.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 134.0K | ★ 466.1K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.25 | $5.05 |
| 52 Week High | $15.27 | $12.41 |
Technical Indicators
Market Signals| Indicator | NFJ | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 40.40 |
| Support Level | $12.71 | $8.86 |
| Resistance Level | $15.20 | $10.64 |
| Average True Range (ATR) | 0.23 | 0.50 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 68.83 | 37.09 |
Price Performance
Historical ComparisonAbout NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. It pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.